文献速递糖尿病

持续C肽分泌与1型糖尿病成人良好CGM指标相关

Persistent C-peptide secretion is associated with favourable CGM metrics in adults with type 1 diabetes.
PubMed 文献 · Diabetologia · 2025-10-30

该研究为英国单中心横断面分析,纳入945例成人1型糖尿病患者,评估随机血浆C肽水平与CGM指标及HbA1c的关系。结果显示较高的C肽水平与更低的血糖低于范围时间、更低的血糖变异、更高的范围内时间及更好的高血糖指标相关,C肽≥100 pmol/l独立关联于达成CGM和HbA1c目标。

要点

  • 随机C肽水平较高的1型糖尿病成人CGM指标更优。
  • C肽≥100 pmol/l独立关联于达成TIR相关目标与HbA1c<53 mmol/mol。
  • C肽<10 pmol/l与10-49 pmol/l间血糖指标无显著差异。

核心结论

  • 常规随机C肽检测可识别更可能达成CGM和HbA1c目标的1型糖尿病成人。
  • C肽≥100 pmol/l时血糖指标差异具有临床意义。

研究设计与样本

  • 英国单中心成人1型糖尿病横断面分析,共纳入945例。
  • 纳入标准为糖尿病病程>1年、采样时随机血糖>4 mmol/l且Freestyle Libre 2 CGM当月数据完整度≥70%。
  • 采用非参数检验和多变量逻辑回归评估C肽分类与CGM/HbA1c结局的关联。

主要发现

  • 较高C肽与较短糖尿病病程(OR 0.87/年,p<0.001)、较大诊断年龄(OR 1.04/年,p<0.001)及男性(OR 1.44,p=0.042)相关。
  • C肽<50 pmol/l者TBR为2%[1-5],C肽101-200 pmol/l者为1%[0-3]。
  • C肽<50 pmol/l者血糖CV为37.5%[34.2-42.0],C肽101-200 pmol/l者为32.5%[29.0-36.6]。
  • C肽<50 pmol/l者TIR为45.0%[32.0-61.0],C肽50-100 pmol/l者为55.0%[37.0-66.5]。
  • C肽<50 pmol/l者TAR>13.9 mmol/l为20.0%[9.0-36.0],C肽50-100 pmol/l者为10.0%[5.5-31.5]。

关键数值与推荐

  • C肽≥100 pmol/l独立关联于达成TBR<4%(OR 5.4,p<0.001)。
  • C肽≥100 pmol/l关联于达成HbA1c<53 mmol/mol(7%)(OR 1.8,p=0.043)。
  • C肽<10 pmol/l与10-49 pmol/l间无显著血糖指标差异。

临床怎么用

  • 常规随机C肽检测有助于识别更可能达成CGM和HbA1c目标的1型糖尿病成人。
  • C肽≥100 pmol/l可作为个体化治疗决策的参考阈值。
  • 研究结果支持保护残余β细胞功能的临床努力。

局限性

  • 横断面设计无法推断因果关系。
  • 单中心研究,结果外推需谨慎。
  • 随机C肽检测未标准化刺激条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Residual endogenous insulin secretion, reflected by measurable C-peptide, has been linked to improved glycaemic management in type 1 diabetes. We aimed to assess the relationship between random plasma C-peptide levels and continuous glucose monitoring (CGM) metrics in a large, real-world cohort of adults with type 1 diabetes. METHODS: We conducted a cross-sectional analysis of adults with type 1 diabetes attending a single UK centre. Inclusion criteria were diabetes duration >1 year, random plasma glucose >4 mmol/l at C-peptide sampling and ≥70% data completeness on the Freestyle Libre 2 CGM device within the corresponding month. Associations between C-peptide categories (<50 pmol/l to >400 pmol/l) and CGM/HbA1c outcomes were assessed using non-parametric tests and multivariable logistic regression. RESULTS: In total, 945 adults with type 1 diabetes were included with a median age of 45 years (33-57) and median diabetes duration of 18 years (7-29). Of these, 54% were male and median HbA1c was 63 mmol/mol (54-73) (7.9% [7.1-8.8]). Higher C-peptide levels were associated with shorter diabetes duration (OR 0.87 per year, p<0.001), older age at diagnosis (OR 1.04 per year, p<0.001) and male sex (OR 1.44, p=0.042). Higher C-peptide was significantly associated with favourable CGM metrics, including lower time below range (2% [1-5] in those with C-peptide <50 pmol/l vs 1% [0-3] in those with C-peptide 101-200 pmol/l), lower glucose variability (glucose CV 37.5% [34.2-42.0] in those with C-peptide <50 pmol/l vs 32.5% [29.0-36.6] in those with C-peptide 101-200 pmol/l), higher time in range (45.0% [32.0-61.0] in those with C-peptide <50 pmol/l vs 55.0% [37.0-66.5] in those with C-peptide 50-100 pmol/l) and favourable hyperglycaemia measures (time above 13.9 mmol/l 20.0% [9.0-36.0] in those with C-peptide <50 pmol/l vs 10.0% [5.5-31.5] in those with C-peptide 50-100 pmol/l) (p<0.05 for all pairwise comparisons). C-peptide ≥100 pmol/l was independently associated with meeting time below range <4% (OR 5.4, p<0.001), and C-peptide ≥100 pmol/l was also associated with achieving HbA1c <53 mmol/mol (7%) (OR 1.8, p=0.043. No significant glycaemic differences were seen between individuals with C-peptide <10 pmol/l and 10-49 pmol/l. CONCLUSIONS/INTERPRETATION: Random C-peptide measurement in routine care identifies adults with type 1 diabetes who are more likely to achieve CGM and HbA1c targets. Differences in glycaemic metrics are clinically meaningful at thresholds ≥100 pmol/l. These findings support efforts to preserve residual beta cell function and highlight the potential value of C-peptide in individualising therapy.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Stimson RH, Dover AR, Clarke C, et al. Persistent C-peptide secretion is associated with favourable CGM metrics in adults with type 1 diabetes. Diabetologia. 2025. PMID: 41165798. doi:10.1007/s00125-025-06578-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。